Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Articles published by Asher Biotherapeutics

Asher Bio Announces Clinical Trial Collaboration and Supply Agreement on Etakafusp Alfa (AB248) in Combination with Bispecific T-cell Engager in Patients with Small Cell Lung Cancer
From Asher Biotherapeutics
Via Business Wire
Asher Bio Announces Clinical Supply Agreement to Enable Evaluation of Etakafusp Alfa (AB248) in Combination with Rilvegostomig in a Global Phase 1b/2 Study in Non-Small Cell Lung Cancer (NSCLC)
From Asher Biotherapeutics
Via Business Wire
Asher Bio Closes $55 Million Series C Financing to Advance Lead Program into Phase 1b Clinical Trials
From Asher Biotherapeutics
Via Business Wire
Asher Bio to Highlight Pipeline Programs in Presentations at AACR Annual Meeting 2023
From Asher Biotherapeutics
Via Business Wire
Asher Bio Announces Clinical Trial Collaboration with Merck to Evaluate AB248 in Combination with KEYTRUDA® (pembrolizumab) in Patients with Locally Advanced or Metastatic Solid Tumors
From Asher Biotherapeutics
Via Business Wire
Asher Bio to Unveil Two New Immunotherapy Programs, a CD8+ T Cell Targeted IL-21 and a Cis-Targeted IL-2 for Cell Therapy Augmentation, at AACR Annual Meeting
From Asher Biotherapeutics
Via Business Wire
Asher Bio to Present New Preclinical Data Demonstrating Differentiated Profile of AB248, its Lead Cis-targeted IL-2 Immunotherapy, at AACR Annual Meeting
From Asher Biotherapeutics
Via Business Wire
Asher Bio Appoints Ian T. Clark to Its Board of Directors
From Asher Biotherapeutics
Via Business Wire
Asher Bio to Present at Upcoming Investor Conferences
From Asher Biotherapeutics
Via Business Wire
Asher Bio Expands Leadership Team with Three Key Appointments
From Asher Biotherapeutics
Via Business Wire
Asher Bio to Present at 40th Annual J.P. Morgan Healthcare Conference
From Asher Biotherapeutics
Via Business Wire
Asher Bio Showcases Versatility and Broad Applicability of Cis-Targeting Technology for Precision Immunotherapies at Antibody Engineering Conferences
From Asher Biotherapeutics
Via Business Wire
Asher Bio to Present at Upcoming Investor Conferences
From Asher Biotherapeutics
Via Business Wire
Asher Bio Announces New Preclinical Data Demonstrating Best-in-Class Potential of AB248, Its Lead Cis-Targeted Il-2 Immunotherapy
From Asher Biotherapeutics
Via Business Wire
Asher Bio to Present at the Morgan Stanley 19th Annual Global Healthcare Conference
From Asher Biotherapeutics
Via Business Wire
Asher Bio Closes $108 Million Series B Financing
From Asher Biotherapeutics
Via Business Wire
Asher Bio Appoints Leading Experts in Immunology, Oncology and Protein Therapeutics to its Scientific Advisory Board
From Asher Biotherapeutics
Via Business Wire
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.